Multi-institutional, multidisciplinary study looks past antibiotics and sanitation to a third strategy to control infectious disease: Adjusting the landscape of the human body to remove the mechanism that allows pathogens to cause disease.
Dr. Nicole Ehrhart will be appointed to the Ross M. Wilkins, M.D. Limb Preservation University Chair in Musculoskeletal Biology and Oncology at Colorado State University.
Article in journal Bioinformatics from University of Colorado Cancer Center describes a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best “kinase inhibitor” to silence these dangerous genetic causes of disease.
Published today in Cancer Discovery, results of LOXO-101 against TRK fusion cancer confirm that stage IV patient's tumors had substantially regressed. With four months of treatment, additional CT scans demonstrated almost complete disappearance of the largest tumors.
A paper published today in the Proceedings of the National Academy of Sciences argues against the commonly held "accumulation of mutations" model of oncogenesis in favor of a model that depends on evolutionary pressures acting on populations of cells.
Lancet Oncology reports phase III clinical trial results of necitumumab against stage IV non-small cell lung cancer
Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.
A University of Colorado Cancer Center study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 shows decreased sexual activity in women following treatment for gynecologic cancers, down from 6.1-6.8 times per month before treatment to 2.6-4.9 times per month after treatment.
Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor. Progression-free survival (PFS) in patients previously treated with crizotinib was 13.4 months.
Obesity is a risk factor for breast cancer. A multi-institutional study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 shows that female breast cancer survivors are able to lose weight through modest lifestyle changes.
Cancer caregivers are stressed, potentially impacting the quality of the care they give. A University of Colorado Cancer Center clinical trial demonstrates how to help.
Study of 11,626 people shows that, all else equal, smokers are 60 percent less likely to vote than nonsmokers.
Analagous to the NCI-60, a new panel of authenticated K9 cancer cell lines presented at AACR 2015 lets veterinary researchers experiment with known cells.
While dietary supplements may be advertised to promote health, a forum at the American Association for Cancer Research (AACR) Annual Meeting 2015 by University of Colorado Cancer Center investigator Tim Byers, MD, MPH, describes research showing that over-the-counter supplements may actually increase cancer risk if taken in excess of the recommended dietary amount.
"It's very simple: tumors from mice that were initially fed silibinin had fewer cancer stem cells, were smaller, had lower metabolisms and showed decreased growth of new blood vessels," says University of Colorado Cancer Center researcher.
At AACR, joint study by NCI and University of Colorado Cancer Center shows TERT is most commonly mutated gene in bladder cancer.
In a major symposium at the American Association for Cancer Research (AACR) Annual Meeting 2015, University of Colorado Cancer Center investigator Tim Byers, MD, MPH, examines research demonstrating the link between cancer, diabetes and cardiovascular disease.
Results presented at AACR 2015 show oncogene recognized in NSCLC in small cell lung cancer, as well, implying that medicines in development for the first may be applicable to second.
New work by the University of Colorado Cancer Center presented at AACR 2015 demonstrates a gene expression model that predicts canine osteosarcoma response to doxorubicin, potentially allowing veterinary oncologists to better choose which drug to use with their patients.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right